共 76 条
Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia
被引:60
作者:
Solmi, Marco
[1
,2
,3
]
Veronese, Nicola
[3
,4
]
Thapa, Nita
[5
]
Facchini, Silvia
[4
]
Stubbs, Brendon
[6
,7
]
Fornaro, Michele
[8
]
Carvalho, Andre F.
[9
,10
]
Correll, Christoph U.
[11
,12
,13
,14
]
机构:
[1] Univ Padua, Dept Neurosci, Via Giustiniani 2, I-35128 Padua, Italy
[2] Mental Hlth Dept, Local Hlth Unit 17, ULSS 17, Padua, Italy
[3] Inst Clin Res & Educ Med IREM, Padua, Italy
[4] Univ Padua, Geriatr Sect, Dept Med DIMED, Padua, Italy
[5] Kaski Sewa Hosp & Res Ctr, Pokhara, Nepal
[6] South London & Maudsley NHS Fdn Trust, Physiotherapy Dept, London, England
[7] Kings Coll London, Inst Psychiat Psychol & Neurosci, Hlth Serv & Populat Res Dept, London, England
[8] Columbia Univ, New York Psychiat Inst, New York, NY USA
[9] Univ Fed Ceara, Dept Clin Med, Fac Med, Fortaleza, Ceara, Brazil
[10] Univ Fed Ceara, Translat Psychiat Res Grp, Fac Med, Fortaleza, Ceara, Brazil
[11] Northwell Hlth, Psychiat Res, Zucker Hillside Hosp, Glen Oaks, NY USA
[12] Hofstra Northwell Sch Med, Hempstead, NY USA
[13] Feinstein Inst Med Res, Manhasset, NY USA
[14] Albert Einstein Coll Med, Bronx, NY 10467 USA
关键词:
Minocycline;
schizophrenia;
efficacy;
safety;
meta-analysis;
systematic review;
CONSENSUS COGNITIVE BATTERY;
ADD-ON TREATMENT;
NEGATIVE SYMPTOMS;
DOUBLE-BLIND;
MICROGLIAL ACTIVATION;
CEREBRAL PERFUSION;
RATING-SCALE;
RECENT-ONSET;
GLUTAMATE;
INFLAMMATION;
D O I:
10.1017/S1092852916000638
中图分类号:
R74 [神经病学与精神病学];
学科分类号:
摘要:
Objective. Our aim was to perform an updated systematic review and meta-analysis on the efficacy and safety of adjunctive minocycline as a treatment of schizophrenia. Methods. We conducted a PubMed/Scopus database search from inception to 3 February 2016 for randomized, placebo-controlled trials (RCTs), open non-randomized studies, and case reports/series evaluating minocycline in patients with schizophrenia. Random-effects meta-analysis of positive, negative, depressive, and cognitive symptom rating scales, discontinuation and adverse effects rates calculating standardized mean difference (SMD), and risk ratios95% confidence intervals (CI95%) were calculated. Results. Six RCTs were eligible (minocycline n=215, placebo n=198) that demonstrated minocycline's superiority versus placebo for reducing endpoint Positive and Negative Syndrome Scale (PANSS) total scores (SMD=-0.59; CI95%=[1.15, -0.03]; p=0.04), negative (SMD=-0.76; CI95%=[-1.21, -0.31]; p=0.001); general subscale scores (SMD=-0.44; CI95%=[-0.88, -0.00]; p=0.05), Clinical Global Impressions scores (SMD=-0.50; CI95%=[-0.78, -0.22]; p<0.001); and executive functioning (SMD=0.22; CI95%=[0.01, 0.44]; p=0.04). Endpoint PANSS positive symptom scores (p=0.13), depression rating scale scores (p=0.43), attention (p=0.47), memory (p=0.52), and motor speed processing (p=0.50) did not significantly differ from placebo, before execution of a trim-and-fill procedure. Minocycline did not differ compared to placebo on all-cause discontinuation (p=0.56), discontinuation due to inefficacy (p=0.99), and intolerability (p=0.51), and due to death (p=0.32). Data from one open-label study (N=22) and three case series (N=6) were consistent with the metaanalytic results. Conclusions. Minocycline appears to be an effective adjunctive treatment option in schizophrenia, improving multiple relevant disease dimensions. Moreover, minocycline has an acceptable safety and tolerability profile. However, more methodologically sound and larger RCTs remain necessary to confirm and extend these results.
引用
收藏
页码:415 / 426
页数:12
相关论文